Literature DB >> 2556854

Disparate effects of two herpesvirus [corrected] immediate-early gene trans-activators on the HIV-1 LTR.

D M Markovitz1, S Kenney, J Kamine, M S Smith, M Davis, E S Huang, C Rosen, J S Pagano.   

Abstract

The BMLF1 region of the Epstein-Barr virus (EBV) genome and the immediate-early (IE) region of human cytomegalovirus (HCMV) both encode proteins which can trans-activate heterologous promoter/chloramphenicol acetyl transferase (CAT) constructs, including a human immunodeficiency virus type-1 promoter/CAT construct. We demonstrate here that this trans-activation by the EBV BMLF1 gene product, which we have previously shown to be largely post-transcriptional, is reporter gene dependent. In contrast, trans-activation by the HCMV-IE gene product(s), previously shown to be mediated at the RNA level, is seen regardless of whether CAT, human growth hormone, or beta-galactosidase is used as the reporter gene. Mutational analysis revealed no specific cis-acting sequences within the HIV-1 promoter which were required for trans-activation by the HCMV-IE gene product(s).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556854     DOI: 10.1016/0042-6822(89)90591-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Association with the cellular export receptor CRM 1 mediates function and intracellular localization of Epstein-Barr virus SM protein, a regulator of gene expression.

Authors:  S M Boyle; V Ruvolo; A K Gupta; S Swaminathan
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Epstein-Barr virus SM protein interacts with mRNA in vivo and mediates a gene-specific increase in cytoplasmic mRNA.

Authors:  V Ruvolo; A K Gupta; S Swaminathan
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression.

Authors:  Vivian Ruvolo; Lorena Navarro; Clare E Sample; Michael David; Seung Sung; Sankar Swaminathan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Functional analysis of Epstein-Barr virus SM protein: identification of amino acids essential for structure, transactivation, splicing inhibition, and virion production.

Authors:  Vivian Ruvolo; Liang Sun; Karilynn Howard; Seung Sung; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Sankar Swaminathan
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  The Epstein-Barr virus nuclear protein SM is both a post-transcriptional inhibitor and activator of gene expression.

Authors:  V Ruvolo; E Wang; S Boyle; S Swaminathan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

6.  The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent.

Authors:  E B Quinlivan; E Holley-Guthrie; E C Mar; M S Smith; S Kenney
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

7.  The human herpesvirus 8 homolog of Epstein-Barr virus SM protein (KS-SM) is a posttranscriptional activator of gene expression.

Authors:  A K Gupta; V Ruvolo; C Patterson; S Swaminathan
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA.

Authors:  C R Brown; M S Nakamura; J D Mosca; G S Hayward; S E Straus; L P Perera
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Human GLI-2 is a tat activation response element-independent Tat cofactor.

Authors:  C M Browning; M J Smith; N M Clark; B R Lane; C Parada; M Montano; V N KewalRamani; D R Littman; M Essex; R G Roeder; D M Markovitz
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Identification of a transactivating function mapping to the putative immediate-early locus of human herpesvirus 6.

Authors:  M E Martin; J Nicholas; B J Thomson; C Newman; R W Honess
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.